Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. AVNS
AVNS logo

AVNS Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
24.940
Open
24.910
VWAP
24.91
Vol
1.39M
Mkt Cap
1.17B
Low
24.865
Amount
34.64M
EV/EBITDA(TTM)
13.64
Total Shares
46.85M
EV
1.19B
EV/OCF(TTM)
32.33
P/S(TTM)
1.60
Avanos Medical, Inc. is a medical technology company focused on delivering medical device solutions. It offers healthcare needs, such as providing nutrition to patients from hospital to home and reducing the use of opioids while helping patients move from surgery to recovery. The Specialty Nutrition Systems portfolio of products includes enteral feeding, which consist of MIC-KEY enteral feeding tubes and Corpak patient feeding solutions, and Neonate solutions feeding products consist of NeoMed neonatal and pediatric feeding solutions. It also includes Nexus TKO, an anti-reflux needleless connector technology. The Pain Management and Recovery is a portfolio of non-opioid pain solutions including surgical pain and recovery products such as ON-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems, as well as Radiofrequency Ablation solutions, which provide invasive pain relief therapies, such as COOLIEF, Trident and ESSENTEC RFA products.
Show More

Events Timeline

(ET)
2026-07-02
10:30:00
Avanos Medical and AIP to Complete Acquisition
select
2026-04-14 (ET)
2026-04-14
16:20:00
Major Averages Rise on Renewed U.S.-Iran Diplomacy Optimism
select
2026-04-14
12:00:00
Major U.S. Averages Broadly Higher, Nasdaq Up 1.66%
select
2026-04-14
06:10:00
Avanos Acquired by American Industrial Partners for Approximately $1.27B
select
2026-02-24 (ET)
2026-02-24
07:10:00
Company Reports Q4 Revenue of $180.9M
select
2026-02-24
07:10:00
Sees 2026 Revenue at $700M-$720M
select
2026-01-20 (ET)
2026-01-20
08:10:00
Avanos Medical and Siemens Healthineers Announce Strategic Co-Marketing Agreement
select

News

PRnewswire
8.5
07-02PRnewswire
Avanos and AIP Merger Receives Regulatory Approval
  • Merger Progress: Avanos and American Industrial Partners (AIP) announced the receipt of all necessary regulatory approvals, with the merger expected to close by July 27, 2026, marking a significant milestone in their collaboration and further driving Avanos's innovation and growth.
  • Shareholder Meeting Scheduled: Avanos will hold a special shareholder meeting on July 22, 2026, to vote on the merger proposal, ensuring shareholder support is crucial for the smooth progression of the transaction, reflecting the company's commitment to stakeholder engagement.
  • Leadership Outlook: Avanos CEO David C. Pacitti stated that the receipt of regulatory approvals is a result of strong collaboration, signaling the company's entry into a new phase of growth focused on delivering superior medical device solutions.
  • AIP Investment Background: AIP manages approximately $17.8 billion in assets and focuses on investing in high-quality engineered product businesses, and post-merger, it will leverage its extensive industry experience and resources to support Avanos in achieving long-term value growth.
Newsfilter
8.5
07-02Newsfilter
Avanos and AIP Merger Receives Regulatory Approval
  • Merger Progress: Avanos Medical and American Industrial Partners announced the receipt of all necessary regulatory approvals, with the merger expected to close by July 27, 2026, marking a significant step in the company's strategic transformation.
  • Shareholder Meeting Arrangement: Avanos will hold a special shareholder meeting on July 22, 2026, to vote on the merger proposal, ensuring shareholder support is crucial for the smooth execution of the transaction.
  • Leadership Outlook: Avanos CEO David C. Pacitti stated that the regulatory approval is a result of strong collaboration between the two organizations, signaling the company's entry into a new phase of innovation and growth, enhancing its competitive edge in medical device solutions.
  • AIP's Investment Potential: AIP, managing approximately $17.8 billion in assets, aims to drive Avanos's next phase of growth and commercial execution through their partnership, which is expected to deliver superior solutions in the medical device industry.
NASDAQ.COM
9.5
06-29NASDAQ.COM
Tactile Systems Technology Shares Rise 8.1% on Strong Volume
  • Strong Price Performance: Tactile Systems Technology's shares rose 8.1% in the last trading session, closing at $30.28 with significantly higher-than-average trading volume, reflecting market optimism about its future performance.
  • Business Growth Momentum: The company continues to show growth in its lymphedema and airway clearance business lines, with expected quarterly earnings of $0.14 per share and revenues projected at $85.54 million, representing an 8.4% year-over-year increase.
  • Stable Earnings Expectations: Although the consensus EPS estimate has remained unchanged over the past 30 days, the rising interest in Tactile Systems Technology indicates investor confidence in its future profitability.
  • Industry Ranking Stability: Tactile Systems Technology currently holds a Zacks Rank of 3 (Hold), similar to its peer Avanos Medical, which also saw a slight increase in share price, indicating overall stability in the medical device sector.
PRnewswire
8.5
06-25PRnewswire
Investigation into Corebridge and Equitable Holdings Merger Terms
  • Merger Investigation: Halper Sadeh LLC is investigating the merger between Corebridge Financial, Inc. and Equitable Holdings, Inc., where each share of Corebridge common stock will be exchanged for 1.0000 shares of the combined company, resulting in Corebridge shareholders owning approximately 51% of the new entity, which may affect shareholder rights and options.
  • Shareholder Rights Protection: The law firm encourages shareholders of both Corebridge and Equitable to reach out to discuss their rights and options at no cost, indicating potential risks and legal issues that shareholders may face during the merger process.
  • Avanos Medical Sale: Avanos Medical, Inc. is being sold to affiliates of American Industrial Partners for $25.00 per share in cash, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures on behalf of shareholders, highlighting the importance of protecting shareholder interests.
  • Legal Service Commitment: Halper Sadeh LLC states that it will handle related matters on a contingent fee basis, meaning shareholders will not be responsible for legal fees, which aims to reduce the financial burden on shareholders and enhance their confidence in pursuing their rights.
Globenewswire
7.0
06-24Globenewswire
Investor Rights Law Firm Investigates Multiple Companies
  • Investigation Focus: Halper Sadeh LLC is investigating Apogee Therapeutics, Inc. (NASDAQ: APGE) for its sale to AbbVie at $135.11 per share, potentially infringing on shareholder rights.
  • Shareholder Rights: Open Lending Corporation (NASDAQ: LPRO) is being sold to ANV Group Holdings Ltd. for $3.15 per share, with Halper Sadeh LLC urging shareholders to be aware of their rights and options.
  • Legal Consultation: Huntsman Corporation (NYSE: HUN) is selling to Olin Corporation for 0.5476 shares of Olin per Huntsman share, and Halper Sadeh LLC offers no-cost legal consultations to help shareholders understand their legal rights.
  • Compensation Requests: Avanos Medical, Inc. (NYSE: AVNS) is being sold to American Industrial Partners for $25.00 per share, and Halper Sadeh LLC may seek increased compensation and other relief measures to protect shareholder interests.
Globenewswire
8.5
06-23Globenewswire
Monteverde Law Firm Investigates Multiple Company Transactions
  • Shareholder Compensation Investigation: Monteverde Law Firm is investigating Open Lending Corporation's transaction, where shareholders are expected to receive $3.15 per share in cash, reflecting the company's market value and potentially impacting shareholder confidence.
  • Huntsman Corporation Transaction: Huntsman shareholders will receive 0.5476 shares of Olin Corporation for each share held, which may influence Huntsman's market performance and future strategic direction following the transaction.
  • Cross Country Healthcare Shareholder Vote: Shareholders of Cross Country Healthcare, Inc. are expected to receive $13.25 per share in cash, with the shareholder vote scheduled for July 16, 2026, making this date critical for the company's future shareholder structure and market response.
  • Avanos Medical Transaction: Avanos Medical shareholders will receive $25.00 per share in cash, with the shareholder vote set for July 22, 2026, indicating a potential restructuring of the company's capital and its competitive position in the market.

Valuation Metrics

The current forward P/E ratio for Avanos Medical Inc (AVNS.N) is 30.67, compared to its 5-year average forward P/E of 16.96. For a more detailed relative valuation and DCF analysis to assess Avanos Medical Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
16.96
Current PE
30.67
Overvalued PE
22.39
Undervalued PE
11.53

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
7.02
Current EV/EBITDA
15.47
Overvalued EV/EBITDA
16.57
Undervalued EV/EBITDA
-2.52

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.38
Current PS
1.56
Overvalued PS
1.80
Undervalued PS
0.97

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

list of stocks to daytrade
Intellectia · 53 candidates
Market Cap: >= 50.00MPrice: $2.00 - $100.00New High Low: 52w_High, 52w_LowList Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 300,000
Ticker
Name
Market Cap$
top bottom
WULF logo
WULF
Terawulf Inc
8.25B
AVNS logo
AVNS
Avanos Medical Inc
675.76M
CAG logo
CAG
Conagra Brands Inc
6.94B
HST logo
HST
Host Hotels and Resorts, Inc
13.93B
ASX logo
ASX
ASE Technology Holding Co Ltd
59.12B
APLS logo
APLS
Apellis Pharmaceuticals Inc
5.22B
Stocks Bullish Tomorrow
Intellectia · 75 candidates
Moving Average Relationship: PriceAboveMA20Option Sentiments: BullishOne Day Rise Prob: >= 60One Day Predict Return: >= 1.0%Monthly Average Dollar Volume: >= 500,000
Ticker
Name
Market Cap$
top bottom
EHAB logo
EHAB
Enhabit Inc
554.91M
FET logo
FET
Forum Energy Technologies Inc
526.00M
BLFY logo
BLFY
Blue Foundry Bancorp
293.98M
GSBC logo
GSBC
Great Southern Bancorp Inc
704.33M
GORO logo
GORO
Gold Resource Corp
242.79M
AVNS logo
AVNS
Avanos Medical Inc
641.97M

Whales Holding AVNS

B
Blackhill Capital, Inc
Holding
AVNS
+22.41%
3M Return
A
Armistice Capital LLC
Holding
AVNS
+16.42%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Avanos Medical Inc (AVNS) stock price today?

The current price of AVNS is 24.93 USD — it has increased 1.22

What is Avanos Medical Inc (AVNS)'s business?

Avanos Medical, Inc. is a medical technology company focused on delivering medical device solutions. It offers healthcare needs, such as providing nutrition to patients from hospital to home and reducing the use of opioids while helping patients move from surgery to recovery. The Specialty Nutrition Systems portfolio of products includes enteral feeding, which consist of MIC-KEY enteral feeding tubes and Corpak patient feeding solutions, and Neonate solutions feeding products consist of NeoMed neonatal and pediatric feeding solutions. It also includes Nexus TKO, an anti-reflux needleless connector technology. The Pain Management and Recovery is a portfolio of non-opioid pain solutions including surgical pain and recovery products such as ON-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems, as well as Radiofrequency Ablation solutions, which provide invasive pain relief therapies, such as COOLIEF, Trident and ESSENTEC RFA products.

What is the price predicton of AVNS Stock?

Wall Street analysts forecast AVNS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVNS is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Avanos Medical Inc (AVNS)'s revenue for the last quarter?

Avanos Medical Inc revenue for the last quarter amounts to 182.20M USD, increased 8.78

What is Avanos Medical Inc (AVNS)'s earnings per share (EPS) for the last quarter?

Avanos Medical Inc. EPS for the last quarter amounts to 0.11 USD, decreased -21.43

How many employees does Avanos Medical Inc (AVNS). have?

Avanos Medical Inc (AVNS) has 2287 emplpoyees as of July 03 2026.

What is Avanos Medical Inc (AVNS) market cap?

Today AVNS has the market capitalization of 1.17B USD.